Dr. John C. McCann, MD

Dr. McCann practices at Baystate Medical Center in Springfield, Massachusetts, part of Baystate Health.

Dr. McCann's NPI, 1952323271, was assigned on July 24, 2006. Dr. McCann graduated from University of Massachusetts Medical School in 1988. Dr. McCann holds Massachusetts license 72771.

Dr. McCann's primary practice is Baystate Medical Center, at 759 Chestnut Street, Springfield, MA 01199 in Hampden County. The practice phone is (413) 794-0000.

Dr. McCann's primary practice is Baystate Medical Center in Springfield, Massachusetts, part of Baystate Health. Dr. McCann is also affiliated with Baystate Noble Hospital. The medical group on file is Baystate Medical Practices. Dmand AI also links Dr. McCann to 2 more hospitals, 2 hospices, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. McCann practices, 8 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. McCann's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. McCann is licensed in Massachusetts.

CMS data shows 1,057 Medicare services from Dr. McCann across 6 procedure codes in 2024, for 396 Medicare patients. Medicare paid $84,505 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 396 Medicare patients who saw Dr. McCann in 2024. The largest group is 65 to 74, with 167 patients. 75% of them have high blood pressure, and 69% have cancer. 28% are also on Medicaid. Their average risk score is 2.90, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. McCann's median patient age at 73, with 44% women.

In 2024, Dr. McCann wrote 1,078 Medicare Part D claims for 207 patients. 69% of them were for generic drugs. CMS names the drug for 821 of them, across 19 drugs with 11 or more claims each, at $3,294,618 in total drug cost. In 2023, CMS named 692 claims across 19 drugs.

Dr. McCann accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. McCann as offering telehealth.

Dmand AI links 1 paper to Dr. McCann in 2019. Dr. McCann's most frequent co-authors are Alan P. Lyss, MD, Nathan A. Pennell, MD, PhD and Suresh Sakkarai Ramalingam, MD.

Dmand AI links Dr. McCann to 10 clinical trials, 6 of them phase 3 studies. 9 are still active or recruiting. Conditions studied include Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung and Melanoma. National Cancer Institute (NCI) sponsors the most, 9.

CMS Open Payments shows 11 general payments to Dr. McCann from 5 drug and device companies from 2016 to 2021. Speaker and faculty fees make up the largest share, 72% of the total. Boehringer Ingelheim Pharmaceuticals, Inc. paid the most, $676.

Dr. McCann graduated from University of Massachusetts Medical School in 1988.